The therapeutic landscape for urothelial carcinoma is rapidly evolving with the implementation of new therapeutic options, making multidisciplinary collaboration essential for personalized treatment strategy. MDT ensure optimal diagnostical pathways, establishment of comprehensive treatment strategies, and thus potential survival benefits.
Neuenschwander et al. (Tue,) studied this question.